Related Experiment Video
Updated: Jul 4, 2026
06:04
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
A practical approach for bridging anticoagulation after mechanical heart valve replacement
Volker Steger1, Dorothee H Bail, Daniela Graf
1Department of Thoracic Surgery, Schillerhöhe Hospital, Gerlingen, Germany. vrsteger@gmx.de
The Journal of Heart Valve Disease
|July 3, 2008
Summary
A fixed 40 mg dose of enoxaparin twice daily is a feasible and safe bridging anticoagulation for mechanical heart valve replacement patients. This protocol simplifies management by eliminating the need for laboratory monitoring and dose adjustments.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Surgery
Background:
- Mechanical heart valve replacement necessitates bridging anticoagulation to prevent thromboembolism.
- Traditional protocols often require dose adjustments based on patient weight and renal function.
- A modified protocol using fixed-dose enoxaparin was implemented in 2000.
Purpose of the Study:
- To evaluate the feasibility and safety of a fixed 40 mg enoxaparin twice daily bridging protocol.
- To assess the rates of thromboembolism and hemorrhage associated with this protocol.
- To compare the efficacy of this modified protocol to full-dose regimens.
Main Methods:
- Retrospective study of 256 patients undergoing mechanical heart valve replacement (April 2000 - December 2004).
- Patients received fixed 40 mg enoxaparin subcutaneously twice daily for a mean of 6.7 days post-surgery.
- Dosage was approximately 55% of the recommended safe dose.
Main Results:
- 18 minor bleeding events (7%) and 2 arterial thromboses (0.7%) were observed.
- Mitral valve replacement was a significant risk factor for minor bleeding (p = 0.005).
- Prosthetic valve function was confirmed as regular by echocardiography at discharge.
Conclusions:
- The modified fixed-dose enoxaparin protocol is feasible and safe in the postoperative cardiac surgery setting.
- Efficacy appears equivalent to full-dose heparin protocols, simplifying patient management.
- Further prospective multi-center studies are recommended to confirm these findings.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...